Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 14;14(3):712.
doi: 10.3390/genes14030712.

Two oncomiRs, miR-182-5p and miR-103a-3p, Involved in Intravenous Leiomyomatosis

Edyta Barnaś  1 , Joanna Ewa Skręt-Magierło  2 , Sylwia Paszek  3 , Ewa Kaznowska  2 , Natalia Potocka  3 , Andrzej Skręt  2 , Agata Sakowicz  4 , Izabela Zawlik  2   3
Affiliations

Two oncomiRs, miR-182-5p and miR-103a-3p, Involved in Intravenous Leiomyomatosis

Edyta Barnaś et al. Genes (Basel). .

Abstract

Leiomyomas, also referred to as fibroids, belong to the most common type of benign tumors developing in the myometrium of the uterus. Intravenous leiomyomatosis (IVL) tends to be regarded as a rare type of uterine leiomyoma. IVL tumors are characterized by muscle cell masses developing within the uterine and extrauterine venous system. The underlying mechanism responsible for the proliferation of these lesions is still unknown. The aim of the study was to investigate the expression of the two epigenetic factors, oncomiRs miR-182-5p and miR-103a-3p, in intravenous leiomyomatosis. This study was divided into two stages: initially, miR-182-5p and miR-103a-3p expression was assessed in samples coming from intravenous leiomyomatosis localized in myometrium (group I, n = 6), intravenous leiomyomatosis beyond the uterus (group II; n = 5), and the control group, i.e., intramural leiomyomas (group III; n = 9). The expression level of miR-182-5p was significantly higher in samples coming from intravenous leiomyomatosis (group I and group II) as compared to the control group (p = 0.029 and p = 0.024, respectively). In the second part of the study, the expression levels of the studied oncomiRs were compared between seven samples delivered from one woman during a four-year observation. The long-term follow-up of one patient demonstrated significantly elevated levels of both studied oncomiRs in intravenous leiomyomatosis in comparison to intramural leiomyoma samples.

Keywords: epigenetic factors; intravenous leiomyomatosis; miR-103a-3p; miR-182-5p; oncomiRs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Microscopic pictures of intravenous leiomyomatosis. (A) The mass of tumor formula image with a peduncle formula image. Objective 10×, H&E. The scale bar showed 200 μm in distance. Immunohistochemical features of intravenous leiomyomatosis beyond the uterus. (B) Strong positivity for smooth muscle actin. (C) Estrogen receptors. (D) Progesterone receptors. (E) Desmin. (F) H-caldesmon. Objective 10×.
Figure 2
Figure 2
Correlation of miR-182-5p expression (A) and miR-103a-3p expression (B) with the age in 3 groups: group I (n = 6, green circle), group II (n = 5, red circle), and group III (n = 9, blue circle).
Figure 3
Figure 3
The expression of miR-182-5p (A) and miR- 103a-3p (B) in three groups: group I—intravenous leiomyomatosis located in the myometrium, group II—intravenous leiomyomatosis beyond the uterus, and group III—intramural leiomyomas. The p-values were calculated by the use of Kruskal–Wallis with post hoc Dunn’s test.
Figure 4
Figure 4
Expression of miR-182-5p (A) and miR-103a-3p (B) in intramural leiomyomas samples (n = 3) and intravenous leiomyomatosis (n = 4) from one patient.
See this image and copyright information in PMC

References

    1. Fasih N., Prasad Shanbhogue A.K., Macdonald D.B., Fraser-Hill M.A., Papadatos D., Kielar A.Z., Doherty G.P., Walsh C., McInnes M., Atri M. Leiomyomas beyond the Uterus: Unusual Locations, Rare Manifestations. RadioGraphics. 2008;28:1931–1948. doi: 10.1148/rg.287085095. - DOI - PubMed
    1. Barnaś E., Raś R., Skręt-Magierło J., Wesecki M., Filipowska J., Książek M., Skręt A., Widenka K. Natural history of leiomyomas beyond the uterus. Medicine. 2019;98:e15877. doi: 10.1097/MD.0000000000015877. - DOI - PMC - PubMed
    1. Ordulu Z., Cin P.D., Chong W.W.S., Choy K.W., Lee C., Muto M.G., Quade B.J., Morton C.C. Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma. Genes Chromosom. Cancer. 2010;49:1152–1160. doi: 10.1002/gcc.20824. - DOI - PMC - PubMed
    1. Ma G., Miao Q., Liu X., Zhang C., Liu J., Zheng Y., Shao J., Cheng N., Du S., Hu Z., et al. Different surgical strategies of patients with intravenous leiomyomatosis. Medicine. 2016;95:e4902. doi: 10.1097/MD.0000000000004902. - DOI - PMC - PubMed
    1. Liu Z., Liu J., Segura M.F., Shao C., Lee P., Gong Y., Hernando E., Wei J.-J. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J. Pathol. 2012;228:204–215. doi: 10.1002/path.4000. - DOI - PubMed

LinkOut - more resources